These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31060635)

  • 41. New serotonin/dopamine antagonists for the treatment of schizophrenia: are we making real progress?
    Miyake N; Miyamoto S; Jarskog LF
    Clin Schizophr Relat Psychoses; 2012 Oct; 6(3):122-33. PubMed ID: 23006237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The dopaminergic hypothesis revisited].
    Guillin O
    Encephale; 2006 Oct; 32(5 Pt 4):S908-11; discussion S912. PubMed ID: 17119503
    [No Abstract]   [Full Text] [Related]  

  • 43. Long-acting injectable antipsychotics for prevention and management of violent behaviour in psychotic patients.
    Mohr P; Knytl P; Voráčková V; Bravermanová A; Melicher T
    Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28869705
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
    Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Schizophrenia and schizophrenia spectrum disorders.
    Wright M
    JAAPA; 2020 Jun; 33(6):46-47. PubMed ID: 32452962
    [No Abstract]   [Full Text] [Related]  

  • 46. Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics.
    Luedtke RR; Rangel-Barajas C; Malik M; Reichert DE; Mach RH
    Curr Pharm Des; 2015; 21(26):3700-24. PubMed ID: 26205291
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.
    Witter DP; Holbert RC; Suryadevara U
    Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nonadherence to antipsychotics: the role of positive attitudes towards positive symptoms.
    Moritz S; Hünsche A; Lincoln TM
    Eur Neuropsychopharmacol; 2014 Nov; 24(11):1745-52. PubMed ID: 25444234
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.
    Morrissette DA; Stahl SM
    CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PDE Inhibitors for the Treatment of Schizophrenia.
    Snyder GL; Vanover KE
    Adv Neurobiol; 2017; 17():385-409. PubMed ID: 28956340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dopamine D2-receptor affinity of antipsychotics in relation to subjective well-being in patients with a psychotic disorder.
    de Wit IE; van Dijk FA; Meijer CJ; van Tricht MJ; de Haan L;
    Int Clin Psychopharmacol; 2017 Sep; 32(5):249-255. PubMed ID: 28542034
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Conditioned avoidance response in the development of new antipsychotics.
    Wadenberg ML
    Curr Pharm Des; 2010 Jan; 16(3):358-70. PubMed ID: 20109144
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes.
    Joyce JN; Goldsmith SG; Gurevich EV
    J Psychiatr Res; 1997; 31(2):197-217. PubMed ID: 9278186
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data.
    Takeuchi H; Suzuki T; Bies RR; Remington G; Mamo DC; Pollock BG; Mimura M; Uchida H
    Schizophr Res; 2013 Nov; 150(2-3):373-9. PubMed ID: 24028745
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis: a reply.
    Lako IM; Liemburg EJ; Van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K
    J Clin Psychopharmacol; 2014 Aug; 34(4):532-3. PubMed ID: 24949704
    [No Abstract]   [Full Text] [Related]  

  • 58. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.
    Nakata Y; Kanahara N; Iyo M
    J Psychopharmacol; 2017 Dec; 31(12):1511-1518. PubMed ID: 28925317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evolution of antipsychotic intervention in the schizophrenic psychosis.
    Garver DL
    Curr Drug Targets; 2006 Sep; 7(9):1205-15. PubMed ID: 17017896
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Schizophrenia: from dopamine to glutamate and back.
    Carlsson ML; Carlsson A; Nilsson M
    Curr Med Chem; 2004 Feb; 11(3):267-77. PubMed ID: 14965231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.